A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis

BACKGROUND: Interleukin-6 (IL-6) transduces signals via phosphorylation of STAT3 (pSTAT3). Tocilizumab (TCZ) is an IL-6 receptor blocker, which, when administered intravenously every 4 weeks, efficiently ameliorates rheumatoid arthritis (RA). Since IL-6 signal strength varies among patients with RA,...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Shuntaro, Suzuki, Katsuya, Yoshimoto, Keiko, Kaneko, Yuko, Matsumoto, Yoshihiro, Yamaoka, Kunihiro, Takeuchi, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645925/
https://www.ncbi.nlm.nih.gov/pubmed/29041951
http://dx.doi.org/10.1186/s13075-017-1434-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645925/
https://www.ncbi.nlm.nih.gov/pubmed/29041951
http://dx.doi.org/10.1186/s13075-017-1434-6

Ejemplares similares